The estimated Net Worth of Sean A Cassidy is at least 8.37 百万$ dollars as of 23 February 2024. Mr. Cassidy owns over 1,702 units of Arvinas Inc stock worth over 4,527,889$ and over the last 6 years he sold ARVN stock worth over 1,823,477$. In addition, he makes 2,018,930$ as Chief Financial Officer at Arvinas Inc.
Sean has made over 19 trades of the Arvinas Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 1,702 units of ARVN stock worth 80,079$ on 23 February 2024.
The largest trade he's ever made was exercising 41,959 units of Arvinas Inc stock on 16 February 2021 worth over 671,344$. On average, Sean trades about 7,215 units every 82 days since 2018. As of 23 February 2024 he still owns at least 181,916 units of Arvinas Inc stock.
You can see the complete history of Mr. Cassidy stock trades at the bottom of the page.
Sean A. Cassidy CPA is Chief Financial Officer of the company. Prior to joining Arvinas, Mr. Cassidy served as the Chief Financial Officer of Axerion Therapeutics, Inc., a biotechnology company, from June 2010 to June 2013. He was also the Chief Financial Officer of Curagen Corporation, a biopharmaceutical company, from January 2008 to December 2009. Mr. Cassidy is a certified public accountant and began his career at Deloitte and Touche LLP. Mr. Cassidy holds an M.B.A and a B.S. in Accounting from the University of Connecticut.
As the Chief Financial Officer of Arvinas Inc, the total compensation of Sean Cassidy at Arvinas Inc is 2,018,930$. There are 1 executives at Arvinas Inc getting paid more, with John Houston having the highest compensation of 5,485,840$.
Sean Cassidy is 50, he's been the Chief Financial Officer of Arvinas Inc since 2013. There are 15 older and 3 younger executives at Arvinas Inc. The oldest executive at Arvinas Inc is Laurie Smaldone Alsup, 66, who is the Independent Director.
Sean's mailing address filed with the SEC is C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY, 10118.
Over the last 6 years, insiders at Arvinas Inc have traded over 123,187,141$ worth of Arvinas Inc stock and bought 3,567,290 units worth 69,124,444$ . The most active insiders traders include Capital Management, L.P.Ra ...、Liam Ratcliffe、Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of 1,884,820$. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth 244,472$.
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Arvinas Inc executives and other stock owners filed with the SEC include: